Nicotine and its interaction with β-amyloid protein:: A short review

被引:38
作者
Zamani, MR
Allen, YS
机构
[1] Cardiff Univ, Sch Biosci, Cardiff CF10 3US, S Glam, Wales
[2] Univ Liverpool, Dept Human Anat & Cell Biol, Liverpool L69 3BX, Merseyside, England
关键词
beta-amyloid protein; neurotoxicity; neuroprotection; nicotine; acetylcholine receptor;
D O I
10.1016/S0006-3223(00)01108-2
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Two features of Alzheimer's disease (AD) are beta -amyloid protein (beta AP) deposition and a severe cholinergic deficit. beta -Amyloid protein is a 39- to 43-amino acid transmembrane fragment of a larger precursor molecule, amyloid precursor protein. It is a major constituent of senile plaque, a neuropathologic hallmark of AD, and has been shown to be neurotoxic in vivo and in vitro. The cholinergic neurotransmission system is seen as the primary target of AD. However other systems are also found to show functional deficit. An association between cholinergic deficit and beta AP is suggested by a negative correlation bern,een cigarette smoking and AD. Evidence hitherto suggests that beta AP causes neuronal death possibly via apoptosis by disrupting calcium homeostasis, which may involve direct activation or enhancement of ligand-gated or voltage-dependent calcium channels. Selective second messengers such as protein kinases are triggered that signal neuronal death. Nicotine or acetylcholinesterase inhibitors call partially prevent the neurotoxicity of beta AP in vivo and in vitro. However, the exact mechanism by, which nicotine provides its protective effects is not fully understood, but clearly there are protective roles for nicotine. Here, some aspects of beta AP neurotoxicity and nicotinic intervention as a protective agent are discussed. (C) 2001 Society of Biological Psychiatry.
引用
收藏
页码:221 / 232
页数:12
相关论文
共 131 条
[81]   Cholinesterase inhibitors in the treatment of Alzheimer's disease - A comparison of tolerability and pharmacology [J].
Nordberg, A ;
Svensson, AL .
DRUG SAFETY, 1998, 19 (06) :465-480
[82]  
NORDBERG A, 1993, ACTA NEUROL SCAND, V88, P62
[83]   Increased regional cerebral glucose metabolism and semantic memory performance in Alzheimer's disease: A pilot double blind transdermal nicotine positron emission tomography study [J].
Parks, RW ;
Becker, RE ;
Rippey, RF ;
Gilbert, DG ;
Matthews, JR ;
Kabatay, E ;
Young, CS ;
Vohs, C ;
Danz, V ;
Keim, P ;
Collins, T ;
Zigler, SS ;
Urycki, PG .
NEUROPSYCHOLOGY REVIEW, 1996, 6 (02) :61-79
[84]   beta-Amyloidosis in normal aging and transmitter signaling in human temporal lobe [J].
Perry, EK ;
Court, JA ;
Lloyd, S ;
Johnson, M ;
Griffiths, MH ;
Spurden, D ;
Piggott, MA ;
Turner, J ;
Perry, RH .
NEUROBIOLOGY OF ALZHEIMER'S DISEASE, 1996, 777 :388-392
[85]   NEUROTRANSMITTER ENZYME ABNORMALITIES IN SENILE DEMENTIA - CHOLINE-ACETYLTRANSFERASE AND GLUTAMIC-ACID DECARBOXYLASE ACTIVITIES IN NECROPSY BRAIN-TISSUE [J].
PERRY, EK ;
GIBSON, PH ;
BLESSED, G ;
PERRY, RH ;
TOMLINSON, BE .
JOURNAL OF THE NEUROLOGICAL SCIENCES, 1977, 34 (02) :247-265
[86]   NICOTINIC RECEPTOR ABNORMALITIES IN ALZHEIMERS AND PARKINSONS DISEASES [J].
PERRY, EK ;
PERRY, RH ;
SMITH, CJ ;
DICK, DJ ;
CANDY, JM ;
EDWARDSON, JA ;
FAIRBAIRN, A ;
BLESSED, G .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1987, 50 (06) :806-809
[87]   ALTERATION IN NICOTINE BINDING-SITES IN PARKINSONS-DISEASE, LEWY BODY DEMENTIA AND ALZHEIMERS-DISEASE - POSSIBLE INDEX OF EARLY NEUROPATHOLOGY [J].
PERRY, EK ;
MORRIS, CM ;
COURT, JA ;
CHENG, A ;
FAIRBAIRN, AF ;
MCKEITH, IG ;
IRVING, D ;
BROWN, A ;
PERRY, RH .
NEUROSCIENCE, 1995, 64 (02) :385-395
[88]  
PERRY RH, 1987, J NEURAL TRANSM, P131
[89]   STRUCTURE-ACTIVITY ANALYSES OF BETA-AMYLOID PEPTIDES - CONTRIBUTIONS OF THE BETA-25-35 REGION TO AGGREGATION AND NEUROTOXICITY [J].
PIKE, CJ ;
WALENCEWICZWASSERMAN, AJ ;
KOSMOSKI, J ;
CRIBBS, DH ;
GLABE, CG ;
COTMAN, CW .
JOURNAL OF NEUROCHEMISTRY, 1995, 64 (01) :253-265
[90]  
Pike CJ, 1996, J NEUROCHEM, V67, P1774